National surveillance pilot study unveils a multicenter, clonal outbreak of VIM-2-producing Pseudomonas aeruginosa ST111 in the Netherlands between 2015 and 2017

Pirzadian, Jannette
Persoon, Marjolein C.
Severin, Juliëtte A.
Klaassen, Corné H.W.
de Greeff, Sabine C.
Mennen, Marcel G.
Schoffelen, Annelot F.
Wielders, Cornelia C.H.
Witteveen, Sandra
van Santen-Verheuvel, Marga
Schouls, Leo M.
Vos, Margreet C.
Bode, L.
Troelstra, A.
Notermans, D. W.
Maijer-Reuwer, A.
Leversteijn-van Hall, M. A.
Kluytmans, J. A.J.W.
Spijkerman, I. J.B.
van Dijk, K.
Halaby, T.
Zwart, B.
Diederen, B. M.W.
Voss, A.
Dorigo-Zetsma, J. W.
Ott, A.
Oudbier, J. H.
van der Vusse, M.
Vlek, A. L.M.
Buiting, A. G.M.
Paltansing, S.
de Man, P.
van Griethuysen, A. J.
den Reijer, M.
van Trijp, M.
van Elzakker, E. P.M.
Muller, A. E.
van der Linden, M. P.M.
van Rijn, M.
Wolfhagen, M. J.H.M.
Waar, K.
Schneeberger, P.
Silvis, W.
Schulin, T.
Damen, M.
Dinant, S.
van Mens, S. P.
Melles, D. C.
Cohen Stuart, J. W.T.
van Ogtrop, M. L.

Publication date

December 2021

DOI

Abstract

Verona Integron-encoded Metallo-beta-lactamase (VIM) is the most frequently-encountered carbapenemase in the healthcare-related pathogen Pseudomonas aeruginosa. In the Netherlands, a low-endemic country for antibiotic-resistant bacteria, no national surveillance data on the prevalence of carbapenemase-producing P. aeruginosa (CPPA) was available. Therefore, in 2016, a national surveillance pilot study was initiated to investigate the occurrence, molecular epidemiology, genetic characterization, and resistomes of CPPA among P. aeruginosa isolates submitted by medical microbiology laboratories (MMLs) throughout the country. From 1221 isolates included in the study, 124 (10%) produced carbapenemase (CIM-positive); of these, the majority (95, 7...